HAE Quote, Financials, Valuation and Earnings

Baxter International has a net margin of 9.79% compared to Haemonetics's net margin of 5.19%. Haemonetics's return on equity of 13.51% beat Baxter International's return on equity of 1.33%.

Haemonetics has a consensus price target of $110.80, signalling upside risk potential of 43.56%. On the other hand Baxter International has an analysts' consensus of -- which suggests that it could grow by 39.45%. Given that Haemonetics has higher upside potential than Baxter International, analysts believe Haemonetics is more attractive than Baxter International.

Haemonetics has a beta of 0.383, which suggesting that the stock is 61.749% less volatile than S&P 500. In comparison Baxter International has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.462%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3.56% to investors and pays a quarterly dividend of $0.17 per share. Haemonetics pays -- of its earnings as a dividend. Baxter International pays out 22.06% of its earnings as a dividend. Baxter International's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haemonetics quarterly revenues are $345.5M, which are smaller than Baxter International quarterly revenues of $2.7B. Haemonetics's net income of $33.8M is lower than Baxter International's net income of $140M. Notably, Haemonetics's price-to-earnings ratio is 32.02x while Baxter International's PE ratio is 145.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.92x versus 0.86x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 9.79% compared to Haemonetics's net margin of 11.12%. Haemonetics's return on equity of 13.51% beat Boston Scientific's return on equity of 8.91%.

Haemonetics has a consensus price target of $110.80, signalling upside risk potential of 43.56%. On the other hand Boston Scientific has an analysts' consensus of $99.14 which suggests that it could grow by 10.33%. Given that Haemonetics has higher upside potential than Boston Scientific, analysts believe Haemonetics is more attractive than Boston Scientific.

Haemonetics has a beta of 0.383, which suggesting that the stock is 61.749% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haemonetics quarterly revenues are $345.5M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Haemonetics's net income of $33.8M is lower than Boston Scientific's net income of $468M. Notably, Haemonetics's price-to-earnings ratio is 32.02x while Boston Scientific's PE ratio is 74.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.92x versus 8.37x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 9.79% compared to Haemonetics's net margin of 8.28%. Haemonetics's return on equity of 13.51% beat Globus Medical's return on equity of 2.27%.

Haemonetics has a consensus price target of $110.80, signalling upside risk potential of 43.56%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 13.39%. Given that Haemonetics has higher upside potential than Globus Medical, analysts believe Haemonetics is more attractive than Globus Medical.

Haemonetics has a beta of 0.383, which suggesting that the stock is 61.749% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $345.5M, which are smaller than Globus Medical quarterly revenues of $625.7M. Haemonetics's net income of $33.8M is lower than Globus Medical's net income of $51.8M. Notably, Haemonetics's price-to-earnings ratio is 32.02x while Globus Medical's PE ratio is 124.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.92x versus 4.60x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 9.79% compared to Haemonetics's net margin of 25.43%. Haemonetics's return on equity of 13.51% beat ResMed's return on equity of 23.76%.

Haemonetics has a consensus price target of $110.80, signalling upside risk potential of 43.56%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 9.49%. Given that Haemonetics has higher upside potential than ResMed, analysts believe Haemonetics is more attractive than ResMed.

Haemonetics has a beta of 0.383, which suggesting that the stock is 61.749% less volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Haemonetics pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haemonetics quarterly revenues are $345.5M, which are smaller than ResMed quarterly revenues of $1.2B. Haemonetics's net income of $33.8M is lower than ResMed's net income of $311.4M. Notably, Haemonetics's price-to-earnings ratio is 32.02x while ResMed's PE ratio is 30.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.92x versus 7.09x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.